Changes coming in 2010 for first-line treatment of multiple myeloma

chemo NCI.jpg

According to a study published by Majestic Research's Market Research Group, data presented at the 2009 American Society of Hematology (ASH) 2009 Annual Meeting in December has had a profound effect on the way many hematologists and oncologists intend to treat multiple myeloma, a cancer of the plasma cells.

Specifically, almost half of those specialists polled say they expect to start using the thalidomide analog Revlimid (lenalidomide), the antineoplastic agent Velcade (bortezomib), or both in combination.

In this context, the most recalled study from ASH was MM-015, a Phase III study that looked at the continuous use of Revlimid with Melphalan and Prednisone. Research shows that many experts believed that the results of MM-015 were significant enough to encourage using Revlimid in treating multiple myeloma.

In short, this year we should expect a substantial change to the first-line treatment of this difficult-to-treat cancer.

By Ross Bonander

LymphomaInfo Social